When I entered the early years of Regenerative Medicine about 10 years ago, the approach was initially based on what was termed PRP (Platelet Rich Plasma). Shortly thereafter, BMC (Bone Marrow Concentrate) became dominant while PRP was redefined; and to this day, there is no universal definition of PRP. In my practice, when I provide informed consent to a patient, I offer standard PRP, concentrated PRP and proprietary PRP. While the terms standard and concentrated are self-explanatory, proprietary is a preparation process that not only provides concentrated platelets, it includes the growth factors Interleukin-1Receptor Antagonist Protein (IRAP), Alpha-2 Macroglobulin (A2M), Tumor Necrosis Factor Blocker (TNF-alpha), and many more.
Unfortunately, over the past decade, the use of the term Stem Cell has become commonplace and many so-called stem cell providers and options have been and are being marketed. I have said it before and I will say it again, until August of 2019, the only FDA compliant means of providing a patient with living stem cells for the treatment of an arthritic joint was via concentrated bone marrow. The use of any and all other methodologies is not FDA and FTC compliant; the claims for birth tissue as an approved source of viable cells is erroneous. To learn more, please visit my blog archives.
A reasonable question then is what happened in August of 2019? It is the month wherein Personalized Stem Cells were approved by the FDA for a Clinical Trial. It is the first time that a patient may gain access to pure stem cells for the treatment of an arthritic joint. Heretofore, Bone Marrow Concentrate allowed for the delivery of 10 to 20 thousand Adult Mesenchymal Stem Cells to an arthritic joint. With the FDA approval of the PSC process, I can now provide 10 to 20 million Adult Mesenchymal Stem Cells to the arthritic joint. All this information is further explained on my website sheinkopmd.com.
You may learn more about the Personalized Stem Cell Clinical Trial at personalizedstemcells.com For those patients who do not meet the inclusion criteria for the stem cell methodology for the Trial or who aren’t candidates for bone Marrow Concentrate, do as I have done; consider the Proprietary Platelet Rich Plasma/ Growth Factor option. I realize that this Blog has a lot to consider so let me clarify during an office consultation call (312) 475-1893 to schedule an appointment.